Final answer:
The priority lab finding a nurse should report before administering ceftazidime via IV bolus is impaired kidney function, as indicated by serum creatinine and BUN levels, due to the risk of drug accumulation and potential toxicity.
Step-by-step explanation:
If a nurse is reviewing lab results for a client who is to receive a dose of ceftazidime via IV bolus, the priority lab finding to report would be any indications of impaired kidney function. Ceftazidime is a cephalosporin antibiotic that is eliminated from the body through the kidneys. Impaired kidney function could lead to an accumulation of the drug, potentially causing toxicity. Thus, renal function tests, particularly serum creatinine and blood urea nitrogen (BUN) levels, should be examined prior to administering the medication. The nurse should also be alert for any signs of thrombocytopenia, as antibiotics can sometimes reduce platelet counts, which is another essential lab finding to report.
It is crucial to monitor these lab results because they can directly affect the safety and efficacy of ceftazidime treatment. Prompt communication with the healthcare provider is essential if any abnormalities are detected, to adjust the dose or find an alternative treatment as necessary.